论文部分内容阅读
5例复发后耐药性的晚期淋巴瘤,其中何杰金病1例,非何杰金淋巴瘤4例,分期Ⅲ_B 1例,Ⅳ_B 4例。骨髓涂片及活检均示造血功能正常,未见淋巴瘤细胞浸润。采用一次性大剂量环磷酰胺化疗和全淋巴结以及累及脏器的~(60)钴照射,并结合自身骨髓移植治疗(简称 ABMT-CI)。ABMT-CI 后48小时,患者肿大的淋巴结开始缩小,至第3～4周有3例获得完全缓解,2例部分缓解;缓解时间1～9个月。其中2例至今仍处于缓解状态。外周血白细胞治疗后第9天下降最低(66～2,000/mm~3)、血小板在第17天最低(6～4万)。一个月后血象及免疫功能基本恢复正常。实践证明 ABMT-CI 方案具有疗程短、见效快、作用较强而副反应可耐受的特点,为复发后耐药性的晚期淋巴瘤提供了再次缓解机会。
Five cases of late-stage drug-resistant advanced lymphomas, including 1 case of Hodgkin’s disease, 4 cases of non-Hodgkin’s lymphoma, 1 case of stage Ⅲ_B and 4 cases of Ⅳ_B. Bone marrow smears and biopsy showed hematopoietic function was normal, no lymphoma cell infiltration. A one-time high-dose cyclophosphamide chemotherapy and all-lymph nodes and organs involved in the (60) cobalt irradiation, combined with its own bone marrow transplantation therapy (ABMT-CI). Forty-eight hours after ABMT-CI, the swollen lymph nodes of the patients began to shrink. Three to four weeks after complete ABMT-CI were completely relieved and two were partially relieved. The time to remission was 1 to 9 months. Two of them are still in remission. The lowest decrease (66 ~ 2,000 / mm ~ 3) on the 9th day after treatment of peripheral blood leukocytes, the lowest on the 17th day (6 ~ 40,000). A month later, blood and immune function returned to normal. Practice has proved that ABMT-CI regimen has the advantages of short course, quick response, strong effect and side-effect tolerable characteristics, and provides a chance for re-developing late-stage drug resistant lymphoma.